Cargando…

Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon‐Free Therapy

BACKGROUND AND AIMS: Sustained virologic response (SVR) to interferon (IFN)‐free therapies ameliorates portal hypertension (PH); however, it remains unclear whether a decrease in hepatic venous pressure gradient (HVPG) after cure of hepatitis C translates into a clinical benefit. We assessed the imp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mandorfer, Mattias, Kozbial, Karin, Schwabl, Philipp, Chromy, David, Semmler, Georg, Stättermayer, Albert F., Pinter, Matthias, Hernández‐Gea, Virginia, Fritzer‐Szekeres, Monika, Steindl‐Munda, Petra, Trauner, Michael, Peck‐Radosavljevic, Markus, García‐Pagán, Juan C., Ferenci, Peter, Reiberger, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155089/ https://www.ncbi.nlm.nih.gov/pubmed/31365764 http://dx.doi.org/10.1002/hep.30885

Ejemplares similares

Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR
por: Semmler, Georg, et al.
Publicado: (2021)

Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Impact of patatin‐like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension
por: Mandorfer, M., et al.
Publicado: (2018)

The impact of hepatic steatosis on portal hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection
por: Scheiner, Bernhard, et al.
Publicado: (2015)

Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease
por: Semmler, Georg, et al.
Publicado: (2021)

Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2018)

Noninvasive Monitoring of Liver Disease Regression after Hepatitis C Eradication Using Gadoxetic Acid-Enhanced MRI
por: Haider, Lukas, et al.
Publicado: (2018)

Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease
por: Balcar, Lorenz, et al.
Publicado: (2023)

Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study
por: Scheiner, Bernhard, et al.
Publicado: (2016)

Direct patient-physician communication via a hepatitis C hotline facilitates treatment initiation in patients with poor adherence
por: Steininger, Lisa, et al.
Publicado: (2020)

Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna
por: Steiner, Sebastian, et al.
Publicado: (2017)

Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients
por: Chromy, David, et al.
Publicado: (2017)

Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis
por: Paternostro, Rafael, et al.
Publicado: (2016)

Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis
por: Paternostro, Rafael, et al.
Publicado: (2018)

HSD17B13 truncated variant is associated with a mild hepatic phenotype in Wilson’s Disease
por: Ferenci, Peter, et al.
Publicado: (2019)

Response‐guided long‐term treatment of chronic hepatitis D patients with bulevirtide—results of a “real world” study
por: Jachs, Mathias, et al.
Publicado: (2022)

Acute hemodynamic response to propranolol predicts bleeding and nonbleeding decompensation in patients with cirrhosis
por: Hofer, Benedikt S., et al.
Publicado: (2022)

Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute‐on‐chronic liver failure
por: Balcar, Lorenz, et al.
Publicado: (2021)

Eligibility for antiviral therapy and treatment uptake in chronic hepatitis B patients referred to a European tertiary care center
por: Jachs, Mathias, et al.
Publicado: (2023)

Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis
por: Simbrunner, Benedikt, et al.
Publicado: (2020)

Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis
por: Burghart, Lukas, et al.
Publicado: (2021)

Alpha-1 antitrypsin Pi∗Z allele is an independent risk factor for liver transplantation and death in patients with advanced chronic liver disease
por: Balcar, Lorenz, et al.
Publicado: (2022)

Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event
por: Balcar, Lorenz, et al.
Publicado: (2022)

The ‘Viennese epidemic’ of acute HCV in the era of direct‐acting antivirals
por: Chromy, David, et al.
Publicado: (2022)

The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes
por: Hartl, Lukas, et al.
Publicado: (2021)

Recent outbreaks of severe hepatitis A virus infections in Vienna
por: Bauer, David, et al.
Publicado: (2020)

Low mortality despite temporary liver dysfunction in severe courses of acute hepatitis E
por: Bauer, David J. M., et al.
Publicado: (2022)

Proton Pump Inhibitor Intake neither Predisposes to Spontaneous Bacterial Peritonitis or Other Infections nor Increases Mortality in Patients with Cirrhosis and Ascites
por: Mandorfer, Mattias, et al.
Publicado: (2014)

Non‐invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease
por: Simbrunner, Benedikt, et al.
Publicado: (2020)

Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma
por: Scheiner, Bernhard, et al.
Publicado: (2019)

HCV hotline facilitates Hepatitis C elimination during the COVID‐19 pandemic
por: Hartl, Lukas, et al.
Publicado: (2022)

Circulating MiRNA-122 Levels Are Associated with Hepatic Necroinflammation and Portal Hypertension in HIV/HCV Coinfection
por: Jansen, Christian, et al.
Publicado: (2015)

Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome
por: Simbrunner, Benedikt, et al.
Publicado: (2023)

Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib
por: Pomej, Katharina, et al.
Publicado: (2021)

Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension
por: Paternostro, Rafael, et al.
Publicado: (2018)

Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function
por: Scheiner, Bernhard, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_k80hsd55fn5au31gdujvmlrq0b